Lv1
30 积分 2021-05-06 加入
Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
2个月前
已完结
The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
3个月前
已完结
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
4个月前
已完结
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)
5个月前
已完结
LPA 1 ‐induced cytoskeleton reorganization drives fibrosis through CTGF‐dependent fibroblast proliferation
5个月前
已完结
[Chinese expert consensus on multidisciplinary discussion of interstitial lung disease]
7个月前
已完结
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
8个月前
已完结
Nerandomilast in Patients with Progressive Pulmonary Fibrosis
10个月前
已完结
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials
10个月前
已完结
Effects of lysophosphatidic acid receptor 1 (LPA1) antagonism on biomarkers in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): data from a randomized phase 2 trial with BMS-986278
11个月前
已关闭
皖公网安备34019202002308
